An observational study in Multiple Myeloma, sponsored by iOMEDICO AG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by iOMEDICO AG · Observational
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.
MYRIAM is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of multiple myeloma in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
Health-realted quality of life in patients with multiple myeloma (MyLife) will be evaluated for up to five years.
Adult patients with multiple myeloma (MM) requiring systemic treatment
Written informed consent
Exclusion Criteria:
Physician's choice according to patient's needs.
Course of treatment (treatment reality)
Documentation of anamnestic data and therapy sequences
Time frame: 5 years per patient
Best Response
Documentation of response rates per line of treatment.
Time frame: 5 years per patient
Progression-free survival
Documentation of progression-free survival per line of treatment.
Time frame: 5 years per patient
Overall survival
Documentation of overall survival time.
Time frame: 5 years per patient
Health-related quality of life (Patient-reported outcome)
EORTC QLQ-C30 core questionnaire.
Time frame: 5 years per patient
Myeloma-specific health-related quality of life (Patient-reported outcome)
EORTC QLQ-MY20, the myeloma specific module.
Time frame: 5 years per patient
Quality of life (Patient-reported outcome)
Brief Pain Inventory (BPI)
Time frame: 5 years per patient
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
iOMEDICO AG